Synovial Sarcoma (SS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Synovial Sarcoma (SS) is a soft tissue
sarcoma that mimics a benign neoplasm due to its slow growth and distal
predisposition. A slow-growing mass, compression symptoms, or irritation to
nearby structures are all common symptoms of SS. These cancers are well-known
for their proclivity for being misdiagnosed. They've been said to look like
arthritis, synovitis, bursitis, hemangiomas, and hematomas, especially when
small calcifications accompany them. SS affects specific areas, with 60 percent
to 70 percent of cases affecting the lower extremity, and is frequently
associated with bursae, tendon sheaths, and joint capsules. Monophasic and
biphasic SS are the two major subtypes of SS histologically. Monophasic tumors,
found in all three of our patients, are made up of spindled cells and have a
better prognosis. They usually present as smaller masses with no metastases.
- The incidence of Synovial Sarcoma (SS) varies from 3.2 to
4.65 cases per million populations in the USA.
Thelansis’s “Synovial Sarcoma (SS) Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Synovial
Sarcoma (SS) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Synovial Sarcoma (SS) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Synovial Sarcoma (SS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment